Oda H, Seki N, Nabeshima S, Oda T, Nishio S, Yokoyama M, Iwata H, Takeuchi M, Matsumoto A, Terado T
Dept. of Urology, Ehime University Medical School.
Gan To Kagaku Ryoho. 1990 Oct;17(10):2051-5.
In sixty-four patients who had TUR-bt for superficial bladder cancer, the effect of intravesical BCG and UFT medication were compared. Group A (n = 20) were treated with BCG, group B (n = 22) were treated with UFT and group C (n = 22) were treated with both agents. The patients were followed up for more than 12 months by cystoscopy at a interval of 3 months, urinary cytology and bladder cold cup biopsy, if necessary. Thirteen of the 20 patients in group A and 13 of the 22 patients in group B were free of tumors, compared to 5 of the 22 patients in group C. Although the recurrence-free-rate in each group does not differ significantly, the combination therapy of intravesical BCG and UFT medication seems to decrease the rate of tumor recurrence for superficial bladder cancer. Side effects of BCG and UFT were tolerated well.
在64例接受经尿道膀胱肿瘤电切术（TUR-bt）治疗浅表性膀胱癌的患者中，比较了膀胱内灌注卡介苗（BCG）和优福定（UFT）的治疗效果。A组（n = 20）接受BCG治疗，B组（n = 22）接受UFT治疗，C组（n = 22）接受两种药物联合治疗。通过膀胱镜检查，必要时结合尿液细胞学检查和膀胱冷杯活检，对患者进行为期12个月以上、间隔3个月的随访。A组20例患者中有13例、B组22例患者中有13例无肿瘤复发，而C组22例患者中只有5例无肿瘤复发。虽然各组的无复发生存率无显著差异，但膀胱内灌注BCG和UFT联合治疗似乎可降低浅表性膀胱癌的肿瘤复发率。BCG和UFT的副作用耐受性良好。
